MBX (MBX Biosciences) ROCE %: -27.00% (As of Mar. 2026)


MBX MBX Biosciences Inc MBX
12 GF Score
Price $50.41
! 2 Warning Signs
View Full Analysis

What is MBX Biosciences ROCE %?

MBX Biosciences MBX +4.07% 12 ROCE % is -27.00% as of Mar. 2026. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MBX Biosciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -27.00%.

MBX Biosciences  (NAS:MBX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MBX Biosciences ROCE % Related Terms

MBX Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for MBX Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MBX Biosciences ROCE % Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROCE %
-61.83 -57.93 -40.38 -31.27

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.06 -38.32 -31.49 -27.24 -27.00
MBX
12GF Score
MBX Biosciences Inc MBX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MBX Biosciences ROCE % Calculation

MBX Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-98.055/( ( (268.535 - 11.051) + (385.144 - 15.495) )/ 2 )
=-98.055/( (257.484+369.649)/ 2 )
=-98.055/313.5665
=-31.27 %

MBX Biosciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-109.06/( ( (385.144 - 15.495) + (452.701 - 14.567) )/ 2 )
=-109.06/( ( 369.649 + 438.134 )/ 2 )
=-109.06/403.8915
=-27.00 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -27.00% mean?
MBX Biosciences (MBX) has a ROCE % of -27.00% as of Mar. 2026.
Is MBX Biosciences' ROCE % too high?
MBX Biosciences' current ROCE % is -27.00%. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' ROCE % compare to ARDX and INBX?
MBX Biosciences' ROCE % of -27.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. MBX Biosciences's current ROCE % is -27.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current ROCE % of -27.00%. The current ROCE % is -27.00%. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For MBX Biosciences (MBX), the current ROCE % is -27.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MBX Biosciences Business Description

Address 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score

Get the complete analysis for MBX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$50.41
Price